ClinicalTrials.gg
CompletedNCT03483571Updated Jun 1, 2021

Dynamics of Subclinical Malaria: Preliminary Study

An observational study in Malaria, sponsored by Duke University. Completed at 1 site in Myanmar. Open to participants aged 6 Months and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-01.

Sponsored by Duke University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,970
Ages
6 Months and older
Sex
All
01

Study summary

This is a short longitudinal preliminary study that aims to describe the dynamics of low-density subclinical malaria to support the final study design of a subsequent matched cohort study. The primary objective is to assess the dynamics of subclinical malaria detected by ultrasensitive PCR over a short duration. The results will be used to guide the design of a matched cohort study of subclinical malaria in Myanmar and along its borders with China and Bangladesh

Read the detailed description

This is a short longitudinal preliminary study that aims to describe the dynamics of low-density subclinical malaria to support the final study design of a subsequent matched cohort study. In this study, a small number of asymptomatic infections detected by ultrasensitive PCR (usPCR) will be followed and tested intensively for three months to measure the temporal dynamics of these infections. A much larger number of uninfected individuals will be followed for just 2-4 weeks (two visits), providing a comparator group for the infected cohort. The validity of our results in a subsequent matched cohort study depends, in part, on our ability to accurately classify infection status using a single usPCR result. In other words, do the investigators have sufficient confidence in the correct classification of malaria infection positive and negative status using usPCR test at the beginning of the study? While there is no gold standard test more sensitive than usPCR, repeated usPCR testing offers a surrogate. Presumably, in a low transmission setting, someone who is truly uninfected on the first testing should remain negative on multiple consecutive tests, but this remains to be confirmed.

The investigators will enroll study participants in up to six study sites, each with >2 villages, towns, unions, refugee camps or plantations, or a single military base. Alternative and additional sites may be added to ensure enough infected cases. The investigators will screen for eligibility (age at least 0.5 year; able \& willing to strictly follow study protocol and to provide written informed consent or assent as appropriate) and enroll and consent eligible individuals. Study procedures are based on test results:

  • RDT-positive: one-time enrollment for data and venous blood collection; Refer to and ensure appropriate treatment by care providing team; No study-related follow up
  • RDT-negative: Collect data and DBS samples; Return to research clinic in 2-4 weeks
  • PCR-negative participants: One follow up visit approximately 2-4 weeks after enrollment
  • PCR-positive participants: Five follow up visits at approximately 4, 6, 8, 10, and 12 weeks (for those with total 12 weeks follow up) or 2, 3, 4, 5 and 6 weeks (for those with total 6 weeks follow up) after enrollment
  • Finger stick blood sampling with be done for RDT and dried blood spot sampling in all participants at each scheduled and unscheduled visit.
  • Venous sampling will be done for participants with RDT+ infections detected at times when study staff trained for venous sampling are present. Blood volumes at any time point are limited to 2 mL for children aged \< 3 years, 3 mL for age 3-5 years, and 5 mL for older children and adults.
  • Estimated duration of study:18 months
02

Conditions studied

  • Malaria

Browse trials for

Keywords

  • asymptomatic
  • submicroscopic
  • PCR
03

In context

Malaria

1,184 studies on the registry are indexed under Malaria; 79 are open to participants now.

This study's enrollment of 2,970 is above the median of 582 across 204 observational studies indexed under Malaria.

Browse Malaria studies →

Lead sponsor

Duke University is the lead sponsor of 2,063 studies on the registry; 273 are open to participants now.

Of its 204 completed or terminated interventional studies of FDA-regulated products, 167 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Sites broadly representative of the range of malaria epidemiologies seen in the region have been identified based on available data on the incidence of clinical malaria and prevalence of subclinical malaria (measured by both standard testing and by usPCR in surveys we have supported). In a staged fashion, initial screening will be undertaken at these sites, starting with the sites in Myanmar, where laboratories proficient in usPCR have been established.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 6 months or older at the time of screening; Written obtained (from the parent/guardian if the subject is less than 18 years old).

Exclusion criteria

Exclusion Criteria:

Any condition which in the view of the investigator makes participation not in the best interests of the prospective participant. Any condition that would interfere with study participation or pose risks to participants. Those with clinical malaria infection as diagnosed by positive RDT may be invited to return and be re-screened for study eligibility after treatment and resolution of their illness.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,970 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Proportion of individuals with initially positive usPCR tests that were followed by 1 or more consecutive positive tests on weekly or biweekly testing

    Proportion of individuals with initially positive usPCR

    Time frame: 12 weeks

  2. Proportion of individuals with initially negative usPCR tests that subsequently had at least one usPCR positive test at a second screening 4 weeks later

    Proportion of individuals with initially negative usPCR tests

    Time frame: 4 weeks

Secondary outcomes

  1. Incidence of falciparum malaria infection by RDT

    Incidence of falciparum malaria infection by RDT

    Time frame: 2 years

  2. Incidence of vivax malaria infection by RDT

    Incidence of vivax malaria infection by RDT

    Time frame: 2 years

  3. Incidence of mixed falciparum/vivax malaria infection by RDT

    Incidence of mixed falciparum/vivax malaria infection by RDT

    Time frame: 2 years

  4. Incidence of falciparum malaria infection by usPCR

    Incidence of falciparum malaria infection by usPCR

    Time frame: 2 years

  5. Incidence of vivax malaria infection by usPCR

    Incidence of vivax malaria infection by usPCR

    Time frame: 2 years

  6. Incidence of mixed falciparum/vivax malaria infection by usPCR

    Incidence of mixed falciparum/vivax malaria infection by usPCR

    Time frame: 2 years

  7. Seroreactivity to polymorphic malaria/mosquito proteins

    Seroreactivity to polymorphic malaria/mosquito proteins

    Time frame: 2 years

07

Study locations

1 site
  • Department of Medical Research
    Yangon, Myanmar
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — PID will not be shared with other researchers

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03483571
Lead sponsor
Duke University
Collaborators
Ministry of Health and Sports, Myanmar, International Centre for Diarrhoeal Disease Research, Bangladesh, National Institute of Parasitic Diseases, China CDC, Defence Services Medical Research Center, Myanmar
Responsible party
Sponsor
First posted
Mar 30, 2018
Start date
Jul 26, 2018
Primary completion
Sep 3, 2019
Completion
Sep 3, 2019
Last update
Jun 1, 2021

Study contacts

Christopher V Plowe, MD, MPH
principal investigator · Duke University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion